Craig Tooman, Silence Therapeutics CEO
Silence unveils more PhI data for siRNA drug in new cardiovascular race targeting Lp(a)
Silence Therapeutics’ siRNA asset showed hints of efficacy in cardiovascular disease patients enrolled in a Phase I trial amid recent readouts from pipeline rivals backed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.